| 著者 |
Koike, Tomomi
| en |
Koike, Tomomi（Personal）
Japan Community Healthcare Organization Kyushu Hospital
|
Search repository
Kawaguchi, Yasunori
| en |
Kawaguchi, Yasunori（Personal）
Asakura Medical Association Hospital
|
Search repository
Shimokawa, Mototsugu
Otsuka, Taiga
Furukawa, Kanami
| en |
Furukawa, Kanami（Personal）
Japan Community Healthcare Organization Kyushu Hospital
|
Search repository
Shinohara, Yudai
| en |
Shinohara, Yudai（Personal）
Japan Community Healthcare Organization Kyushu Hospital
|
Search repository
Shimokawa, Hozumi
| en |
Shimokawa, Hozumi（Personal）
Japan Community Healthcare Organization Kyushu Hospital
|
Search repository
Yoshihiro, Tomoyasu
| en |
Yoshihiro, Tomoyasu（Personal）
Japan Community Healthcare Organization Kyushu Hospital
|
Search repository
Shibuki, Taro
Nakazawa, Junichi
Arima, Shiho
Miwa, Keisuke
Koga, Futa
Ueda, Yujiro
Kubotsu, Yoshihito
Takeshita, Shigeyuki
| en |
Takeshita, Shigeyuki（Personal）
Japanese Red Cross Nagasaki Genbaku Hospital
|
Search repository
Nishikawa, Kazuo
Komori, Azusa
| en |
Komori, Azusa（Personal）
Department of Medical Oncology and Hematology, Oita University Faculty of Medicine, Yufu-shi, Oita, Japan.
|
Search repository
Otsu, Satoshi
| en |
Otsu, Satoshi（Personal）
Department of Medical Oncology and Hematology, Oita University Faculty of Medicine, Yufu-shi, Oita, Japan.
|
Search repository
細川, 歩
WEKO
33635
e-Rad_Researcher
90432111
| ja |
細川, 歩
宮崎大学
|
| ja-Kana |
ホソカワ, アユム
|
| en |
Hosokawa, Ayumu
University of Miyazaki
|
Search repository
Sakai, Tatsunori
Oda, Hisanobu
Kawahira, Machiko
Arita, Shuji
Honda, Takuya
Taguchi, Hiroki
Tsuneyoshi, Kengo
Fujita, Toshihiro
Sakae, Takahiro
Shirakawa, Tsuyoshi
| en |
Shirakawa, Tsuyoshi（Personal）
Clinical Hematology Oncology Treatment Study Group
|
Search repository
Mizuta, Toshihiko
Mitsugi, Kenji
|
|
内容記述 |
Background:
Nanoliposomal irinotecan with fluorouracil and folinic acid (NFF) is a standard regimen for patients with unresectable or recurrent pancreatic cancer (urPC) after gemcitabine-based chemotherapy. However, little is known about the clinical impact of previous chemotherapy on the effects of NFF in the real world.
Objectives:
We retrospectively evaluated whether the efficacy and safety of NFF differed depending on the history of prior chemotherapy among urPC patients receiving NFF.
Design:
This study was conducted using the real-world data of Japanese patients with urPC who received NFF in the multicenter NAPOLEON-2 study.
Methods:
We compared the efficacy and adverse events (AEs) after NFF initiation between previous irinotecan users and non-users, fluorouracil users and non-users, and platinum users and non-users. We also investigated whether the treatment duration of gemcitabine plus nab-paclitaxel (GnP) influenced the efficacy of NFF among patients treated with NFF as a second-line therapy after GnP.
Results:
Overall, 161 patients were enrolled, all of whom had previously received gemcitabine. In the efficacy analysis between irinotecan users and non-users, the median overall survival (OS) was 9.2 and 8.0 months, respectively (hazard ratio (HR) 0.88; p = 0.66). For fluorouracil, the median OS was 9.1 months for users and 7.6 months for non-users (HR 0.98; p = 0.93). For platinum, the median OS was 9.1 months for users and 8.0 months for non-users (HR 0.88; p = 0.67). There was no clinical difference in AEs between irinotecan users and non-users, which affected ⩾10% of patients in both groups. The median OS in the group with previous GnP for ⩾7.8 months was 9.5 months, while it was 4.8 months in the group with GnP for <7.8 months (HR 0.50; p < 0.01).
Conclusion:
NFF may be effective and tolerable, even in patients previously treated with irinotecan-, fluorouracil-, or platinum-based chemotherapy, in the real world. |
fulltext (413 KB)
.png)
